Has Metal-On-Metal Resurfacing Been a Cost-Effective Intervention for Health Care Providers?—A Registry Based Study by Pulikottil-Jacob, Ruth et al.
Citation: Pulikottil-Jacob, Ruth, Connock, Martin, Kandala, Ngianga-Bakwin, Mistry, Hema, 
Grove, Amy, Freeman, Karoline, Costa, Matthew, Sutcliffe, Paul and Clarke, Aileen (2016) 
Has  Metal-On-Metal  Resurfacing  Been  a  Cost-Effective  Intervention  for  Health  Care 
Providers?—A Registry Based Study. PLOS One, 11 (11). e0165021. ISSN 1932-6203 
Published by: Public Library of Science
URL:  http://dx.doi.org/10.1371/journal.pone.0165021 
<http://dx.doi.org/10.1371/journal.pone.0165021>
This  version  was  downloaded  from  Northumbria  Research  Link: 
http://nrl.northumbria.ac.uk/28449/
Northumbria University has developed Northumbria Research Link (NRL) to enable users to 
access the University’s research output. Copyright © and moral rights for items on NRL are 
retained by the individual author(s) and/or other copyright owners.  Single copies of full items 
can be reproduced,  displayed or  performed,  and given to  third parties in  any format  or 
medium for personal research or study, educational, or not-for-profit purposes without prior 
permission or charge, provided the authors, title and full bibliographic details are given, as 
well  as a hyperlink and/or URL to the original metadata page. The content must  not  be 
changed in any way. Full items must not be sold commercially in any format or medium 
without  formal  permission  of  the  copyright  holder.   The  full  policy  is  available  online: 
http://nrl.northumbria.ac.uk/policies.html
This document may differ from the final, published version of the research and has been 
made available online in accordance with publisher policies. To read and/or cite from the 
published version of the research, please visit the publisher’s website (a subscription may be 
required.)
RESEARCH ARTICLE
Has Metal-On-Metal Resurfacing Been a
Cost-Effective Intervention for Health Care
Providers?—A Registry Based Study
Ruth Pulikottil-Jacob1, Martin Connock1, Ngianga-Bakwin Kandala1,2, Hema Mistry1,
Amy Grove1, Karoline Freeman1, Matthew Costa1, Paul Sutcliffe1, Aileen Clarke1*
1 Warwick Evidence, Division of Health Sciences, Warwick Medical School, University of Warwick,
Coventry, United Kingdom, 2 Northumbria University, Department of Mathematics, Physics and Electrical
Engineering, Faculty of Engineering and Environment, Newcastle upon Tyne, United Kingdom
* Aileen.Clarke@warwick.ac.uk
Abstract
Background
Total hip replacement for end stage arthritis of the hip is currently the most common elec-
tive surgical procedure. In 2007 about 7.5% of UK implants were metal-on-metal joint resur-
facing (MoM RS) procedures. Due to poor revision performance and concerns about metal
debris, the use of RS had declined by 2012 to about a 1% share of UK hip procedures. This
study estimated the lifetime cost-effectiveness of metal-on-metal resurfacing (RS) proce-
dures versus commonly employed total hip replacement (THR) methods.
Methodology/Principal Findings
We performed a cost-utility analysis using a well-established multi-state semi-Markov model
from an NHS and personal and social services perspective. We used individual patient data
(IPD) from the National Joint Registry (NJR) for England and Wales on RS and THR surgery
for osteoarthritis recorded from April 2003 to December 2012. We used flexible parametric
modelling of NJR RS data to guide identification of patient subgroups and RS devices which
delivered revision rates within the NICE 5% revision rate benchmark at 10 years. RS proce-
dures overall have an estimated revision rate of 13% at 10 years, compared to <4% for most
THR devices. New NICE guidance now recommends a revision rate benchmark of <5% at 10
years. 60% of RS implants in men and 2% in women were predicted to be within the revision
benchmark. RS devices satisfying the 5% benchmark were unlikely to be cost-effective com-
pared to THR at a standard UK willingness to pay of £20,000 per quality-adjusted life-year.
However, the probability of cost effectiveness was sensitive to small changes in the costs of
devices or in quality of life or revision rate estimates.
Conclusion/Significance
Our results imply that in most cases RS has not been a cost-effective resource and should
probably not be adopted by decision makers concerned with the cost effectiveness of hip
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replacement, or by patients concerned about the likelihood of revision, regardless of patient
age or gender.
Introduction
Hip replacement is a common elective surgical procedure. If an estimated 80,000 replacements
are conducted annually at an average cost of £8,500 per procedure, this would cost the UK
NHS approximately £680 million per annum [1, 2]. The overall post-operative costs are
approximately five times greater than this due to hospital stay and post-operative support [3].
Approximately 80,000 procedures are performed each year and, assuming lifetime revision
rates are about 5% and the average cost of revision surgery is approximately £17,000, prosthesis
failure adds a further £68 million over subsequent years [4]. Total hip replacement is currently
the most commonly used surgical intervention for end stage arthritis of the hip. In 2007 about
7.5% of UK implants were metal-on-metal joint resurfacing (MoM RS) procedures [5], but due
to high revision rates and concerns about metal debris, the use of RS declined to about 1% of
UK hip procedures in 2012. The DePuy Articular Surface Replacement (ASR) device (repre-
senting about 9% of UK RS) was recently withdrawn after unacceptably high revision rates
were observed, and in 2015 Smith and Nephew voluntarily withdrew some BirminghamHip
devices (the most widely used RS device in the UK) on the grounds that in certain populations
(e.g. women) devices with a relatively small head size failed to reach the NICE benchmark for
revision. Similar concerns have led to the near abandonment of metal-on-metal THRs [6–9].
However some people still advocate for RS in the young and active, whose primary implant is
expected to need replacement over their lifetime [1,10]. In particular, it has been argued that
there may be a role for the best RS devices in highly selected patients such as active young men
with a large femoral head size [1,11].
Updated NICE guidance for hip replacement recommends a 10 year revision rate bench-
mark of<5% [12]. The 11th National Joint Registry (NJR) report (2014) estimated that in the
past the RS 10 year revision rate has been about 13% [5]. This compares unfavourably with
10-year revision rates for frequently used THR devices, which are less than 4% and indicates
that, as a class, RS is unlikely to have been cost-effective relative to THR [12–14]. RS devices
produced by at least sixteen different manufacturers have been used in the UK and they differ
with respect to revision rate [5]. It remains an open question whether implantation of any RS
devices or the best RS devices in highly selected patients such as active young men with a large
femoral head size can be cost-effective.
We use data from the National Joint Registry for England andWales to identify RS device-
patient combinations likely to satisfy the NICE benchmark, and to address the question of
whether past use of any RS devices, even those within the 5% revision rate at 10 years, has rep-
resented a cost-effective use of NHS resources.
Methods
Prosthesis categories
The National Joint Registry (NJR) for England andWales supplied individual patient data
(IPD) for RS and THR surgery for osteoarthritis, recorded from April 2003 to December 2012.
Following the approach of others [5,12,13], we used flexible parametricmodelling (Lambert
and Royston 2009) [15] of NJR RS data to guide identification of patient subgroups and RS
devices which delivered revision rates within the NICE 5% revision rate benchmark at 10 years.
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Variables investigated included the following: devicemanufacturer, RS head size, age at pri-
mary intervention, American Society of Anaesthetologists (ASA) grade, and sex Patients were
coded in the NJR as: ASA grade 1 (“normal healthy individuals”); ASA 2 (“mild systemic disease
that does not limit activity”); or ASA grades 3 to 5 (“severe systemic disease that limits activity
but is not incapacitating”, “incapacitating systemic disease which is constantly life threatening”,
and “moribund, not expected to survive 24 hours with or without surgery”). Patients who had a
primary indication for surgery other than osteoarthritis were excluded along with those graded
ASA 3, ASA4 and ASA5 (who represented only 3% of RS recipients), and those receving the
DePuy RS device and data were then stratified according to sex. . .Devices produced by six of
the sixteenmanufaturers which contributed 96% of relevant implants were included, compris-
ing BirminghamHip, Biomet, Centerpulse, Corin, Finsbury andWright UK.Where modelling
indicated that patients and devices had satisfied the NICE benchmark, we pooled device and
patient subgroups by manufacturer with the aim of estimating cost-effectiveness relative to
THRs that satisfy the NICE benchmark.
Multiple manufacturers providing about 150 different THR components are listed in the
NJR. The most commonly used THR devices (covering 62% of all THRs) were selected for
potential comparison with RS on the basis of frequency of use of components (cup component
group; cup component type; cup composition; cup fixation; cup implant type; head component
type; head composition; liner component type; liner composition; stem component type; stem
fixation; stem implant type) [12,16]. S1 Table summarises the characteristics of five frequently
used THR devices which differ according to bearing surfaces, and/or mode of fixation.We
have previously reported that all these devices have shown revision rates within the NICE
benchmark [12].
Economic model
We used the well-established simple multi-state semi-Markov model developed by Fitzpatrick
et al. (Fig 1) [17]; this model has been used repeatedly by others [14,18,19]. In the model,
patients occupy one of four mutually exclusive health states: (1) successful primary THR or RS
surgery (2) revision THR surgery (patients can move into this state more than once but stay in
this health state for one annual cycle only); (3) successful revision THR surgery; (4) dead
(patients may enter this state both due to operative mortality or due to death from other
causes). We assumed that if the initial RS or THR required revision, the patient would be
revisedwith a THR prosthesis.
Model inputs included the following: annual transition probabilities for time to revision and
death, costs, and utilities of health states. The model cycle length was one year. We explored
multiple parametric distributions to model lifetime revision rates using individual patient data
from the NJR. The transition probability to death after cycle one was based on data from the
Office for National Statistics for appropriately aged men and women [20]. An NHS and Social
Servicesperspectivewas chosen for costs and a 3.5% annual discount rate was applied to both
costs and health outcomes [21] All costs are reported in 2014 British Pounds. Table 1 summa-
rises the model input parameters and sources [4,22–26].
The model was run probabilistically, with 1,000 iterations using standard distributions for
input parameters in order to capture uncertainties [27]. Time horizons were 10 years and life-
time (to 100 years of age). Model outputs were mean quality-adjusted life years gained
(QALYs), mean costs accumulated, the estimated probability that a particular prosthesis is
cost-effective at a willingness to pay threshold of £20,000/QALY, and the incremental cost-
effectiveness ratio (ICER in terms of cost/QALY) in scenarios where RS accumulatedmore
QALYs at greater cost than THR.
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Health outcomes
Health outcomes were measured in QALYs [27]. Quality of life data were obtained from the
patient reported outcome measures (PROMS) database for patients who had received a hip
replacement between January 2009 and December 2012 [24]. EQ-5D scores for successful pri-
mary health and revision health states were adjusted for age and sex differences. The age-
related utilities were assumed to be the same for the comparison of RS with THR (see previous
publication for further information on PROMS analysis) [16]. In a sensitivity analysis we used
the utility difference of RS versus THR reported by Edlin et al. (2012), and applied this for the
first two years post-surgery [26]. (see S2 Table).
Resource use and cost estimates
The NHS Supply Chain provided June 2013 costs for components of each prosthesis type and
the total cost of each prosthesis (see previous publication for further information on THR pros-
thesis cost [16] and S3 Table for cost of RS prosthesis). We assumed the costs to be the same
for the BirminghamHip, Biomet and Finsbury prostheses due to lack of cost data for each indi-
vidual prosthesis. The costs of a successful primary THR, RS, revision procedure and successful
revision procedure were taken from the literature [4,25,26]. Costs of primary and revision
THRs included surgery costs, prosthesis costs, hospital ward costs, and follow-up costs
Fig 1. Semi-Markov model structure.
doi:10.1371/journal.pone.0165021.g001
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[4,25,26]. The cost of a successful revision procedure (£16,517) and cost of post-revision follow
up (£394) were assumed to be the same for both RS and THR. The projected Health Services
Cost Index (HSCI) was used to inflate costs to current prices (2014) [28].
Sensitivity analyses
The base case utilized probabilistic sensitivity analysis to assess uncertainty in the model. Sce-
nario analyses included the following: (a) changing the parametric distribution used to model
Table 1. Model inputs for the base case analysis of cost-effectiveness.
Transition probabilities
Health state Mean value SE Source
Surgical mortality* 0.0050 0.001 NJR annual
report22
Risk of re-revision 0.0518 N/A Pennington et al30
Utility inputs
Utilities—Male Mean value SE Beta distribution Parameter α Beta distribution Parameter β Source
Age 40–50 0.736 0.0179 443 159 PROMS24
Age 50–60 0.767 0.0066 3133 952
Age 60–70 0.762 0.0038 9112 2393
Revision surgery 0.575 0.009 1496 1106
Utilities—Female
Age 40–50 0.720 0.0129 872 339 PROMS24
Age 50–60 0.742 0.0058 4287 1491
Age 60–70 0.769 0.0032 13128 3944
Revision surgery 0.553 0.007 2201 1779
Cost inputs
RS versus THR
Cost Mean value £ SE Gamma distribution Parameter α Gamma distribution Parameter β Source
RS comparison
Prosthesis cost 2,808 N/A N/A N/A NHS Supply Chain
Surgery costs (excluding
prosthesis)
1,738 N/A N/A N/A Vale et al.25
Hospital inpatient stay 1,628 N/A N/A N/A Edlin et al.26
Follow-up cost post- RS 509 44 130 4
Revision surgery 16,794 443 1435 12 Vanhegan et al.4
Post revision follow-up 400 30 169 2 Edlin et al.26
THR comparison
Prosthesis cost (CeMoP) 1,575 N/A N/A N/A NHS Supply Chain
Prosthesis cost (CeLCoC) 3,911 N/A N/A N/A NHS Supply Chain
Prosthesis cost (CeCoP) 2,018 N/A N/A N/A NHS Supply Chain
Surgery costs (excluding
prosthesis)
1,738 N/A N/A N/A Vale et al.25
Hospital inpatient stay 1,687 N/A N/A N/A Edlin et al.26
Follow-up cost post- THR 400 30 169 2
Revision surgery 16,794 443 1435 12 Vanhegan et al.4
Post revision follow-up 400 30 169 2 Edlin et al.26
*surgical mortality was the same for THR/RS and revision
doi:10.1371/journal.pone.0165021.t001
Cost-Effectiveness of Metal-On-Metal Resurfacing Procedures versus Total Hip Replacement
PLOS ONE | DOI:10.1371/journal.pone.0165021 November 1, 2016 5 / 13
lifetime revision rates (b) using device costs supplied by manufacturers to the National Institute
for Health and Care Excellence for technology appraisal TA304 [29]; (c) using alternative qual-
ity of life utility values [26]. Additional scenarios investigated included the following: compar-
ing the BirminghamHip, Biomet and Finsburymale patient-device combinations that satisfy
the NICE benchmark versus cemented metal on polythene device (CeMoP), cemented THR
with ceramic on polythene bearing surface (CeCoP) and/or cementless ceramic on ceramic
bearing surface (CeLCoC)THRs.
Results
Six manufacturers of RS components accounted for almost all (96%) of RS interventions (S1
Fig). The BirminghamHip contributed more than half of all RS use. Patient ASA grade and age
distributions were similar betweenmanufacturers (S2 Fig and S3 Fig). Usage of various head
sizes was idiosyncratic and differed between the 6 manufacturers (S4 Fig).
Kaplan-Meier analyses indicated that for all six manufacturers, men experienced lower revi-
sion rates than women. However, even for men, the revision rate was poor for most manufac-
turers and flexible parametric models predicted a low probability of satisfying the 10 year
NICE benchmark (Fig 2). The only device which delivered an overall revision rate within or
near the 10 year benchmark was the BirminghamHip. For women, no manufacturer’s device
delivered a revision rate within the benchmark. All exceeded 5% revision within only 5 years,
and by 10 years, predicted rates in women were all greater than 10% (S5 Fig).
In addition to RS devicemanufacturer and sex, the requirement for revision is likely to be
influenced by the size of the head component and patient age [13]. We therefore estimated the
predicted ten year revision rate for different head sizes using flexible parametric models with
age as a covariate. Graphical examples are shown in S6–S9 Figs.
These flexible parametric models predicted poor 10 year performance for almost all female
RS recipients irrespective of device head size, patient age at intervention or devicemanufac-
turer. Of the 6,646 women provided with RS, only about 2% were in head size-age-manufac-
turer categories likely to satisfy the NICE benchmark for revision. Of 18,720 male RS
recipients, around 60% were estimated to be in such categories. Of these, 87% were Birming-
ham Hip recipients in head size categories of 50 mm or greater, and the rest were mostly recipi-
ents of Finsbury devices with head sizes 48mm or Biomet devices with a 50 to 54 mm head
size.
Fig 3 shows revision performance for the Birmingham hip, Biomet and Finsbury RS devices
in male ASA1 and ASA2 grade patients when head size-patient categories were dichotomized
into those predicted to satisfy and not satisfy the NICE benchmark. Refinement by selecting
for age within head sizes generally improved the revision profile.
The cost-effectiveness of the BirminghamHip, Biomet and Finsbury devices satisfying the
NICE benchmark for revision were compared with THR devices in male ASA 1 and ASA 2
grade patients. For the base case economic analysis we compared the most widely used RS (Bir-
mingham hip, within NICE benchmark) with the most widely used THR device (CeMoP) in
male grade ASA 1 and ASA grade 2 patients. Inputs for the economic analysis are summarised
in Table 2. This analysis indicated that the probability that RS was cost-effective compared to
THR remained low (<4%) at a willingness to pay of £20,000/QALY (for CEAC see S10 Fig).
BirminghamHip accumulated fewer lifetimeQALYs for 40, 50 and 60 year old men; lifetime
costs were greater than for RS by at least £2,900 and RS was dominated by THR for 60 year old
men.
Since the BirminghamHip was the best performing RS device, we performed a sensitivity
analysis in which it was compared with the best performing THR device (CeCoP). In this
–-
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comparison the probability that RS was cost-effectivewas 46% for 40 year old men, and less for
older men.
Fig 2. Kaplan-Meier revision plots (95% CI) and flexible parametric models for different manufacturer’s RS
devices implanted in men graded as ASA 1 (upper panel) or ASA 2 (lower panel). BH = Birmingham Hip;
Bi = Biomet; Ce = Centerpulse; Co = Corin; Fi = Finsbury; Wr = Wright UK.
doi:10.1371/journal.pone.0165021.g002
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Since the mean age for the BirminghamHip recipients was less than that for the CeMoP
and CeCoPTHR devices, we performed a further sensitivity analysis comparing the Birming-
ham Hip with the CeLCoCTHR since this has been used in a younger population than the
other THRs. In this comparison, the probability that the BirminghamHip was cost-effective
was ~76%. However, using alternative plausible models of lifetime revision resulted in a drop
in probability of the BirminghamHip being cost-effective to less than 10% due to poor pre-
dicted performance of RS.
We compared the Biomet RS and Finsbury devices (patient device combinations within the
NICE benchmark for revision shown in Fig 3) with the best performing THR device (CeCoP)
in male grade ASA 1 and ASA grade 2 patients, the probability that RS was cost-effectivewas
<6% at a willingness to pay of £20,000/QALY.
Fig 3. Estimated ten-year revision rates dichotomized by head size-patient combinations satisfying and not satisfying the ten year benchmark
of 5%. The data are for male patients of ASA 1 plus ASA 2 grade receiving RS devices from different manufacturers (the subgroups within the NICE
benchmark for revision were as follows: Finsbury (mean age 51.3 years): head sizes 48 or less and head size 50 if patient age was less than 50 years at
intervention; Biomet (mean age 50.4 years): head size 50 if age less than 55 years, head sizes 52, and 54 if age less than 60 years; Birmingham Hip
(mean age 55.5 years) head sizes 50 or greater and head size 48 if age less than 45 years). Note the more mature data for Birmingham Hip. For clarity the
95% CI of the Kaplan Meier plot for the Finsbury below-benchmark subgroup has been omitted.
doi:10.1371/journal.pone.0165021.g003
Table 2. Cost-effectiveness results for base case analysis Birmingham hip) versus CeMoP comparison for ASA1 plus ASA 2 male patients aged
40, 50 and 60 years.
Age 40 Age 50 Age 60
BHIP CeMoP BHIP CeMoP BHIP CeMoP
Men: 10-year time horizon
Total mean costs £ 12,211 10,348 12,133 10,033 12,024 9,829
Total mean QALYs 7.326 7.321 7.515 7.512 7.4850 7.4841
Incremental cost £ 1,863 2,100 2,194
Incremental QALYs 0.0054 0.0026 0.0009
ICERs (£/QALY) 344,570 811,430 2,376,140
Men: Lifetime horizon
Total mean costs £ 21,479 18,571 19,187 15,908 16,421 13,130
Total mean QALYs 16.587 16.581 14.706 14.705 12.109 12.110
Incremental cost £ 2,908 3,278 3,291
Incremental QALYs 0.0059 0.0013 -0.001
ICERs (£/QALY) 488,836 2,493,847 Dominated
doi:10.1371/journal.pone.0165021.t002
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When manufacturer’s device costs were used instead of NHS Supply Chain costs, the proba-
bility that the BirminghamHip was cost-effective relative to the CeMoP THR device remained
below 5%. In further sensitivity analyses, we applied the one year QOL advantage for RS
reported by Edlin et al. (2012) in the BirminghamHip versus CeMoP comparison; the Bir-
minghamHip was more costly and accumulatedmore QALYs, and the probability that Bir-
minghamHip was cost-effectivewas 100% for 40, 50 and 60 year old men (with NHS Supply
Chain prosthesis costs) [26].
Discussion
Conceptual advantages proposed for resurfacing relative to THR include preservation of bone
and improved durability frommetal-on-metal bearing surfaces; features leading to the percep-
tion that resurfacing is suitable for young and active patients. The age profile of RS recipients
in National Joint Registry reflects this perception, but there is a lack of randomised or other
comparative evidence to underpin this usage and, the observed revision rates for RS are alarm-
ingly poor relative to THR. The single RCT so far conducted indicated a lack of short term
advantage for RS in a mix of male and female patients with a mean age of 56 years [30].
National Joint Registry data for women who have received resurfacing devices highlights poor
revision performance; even when the data are stratified according to devicemanufacturer,
device head size and controlled for patient age, poor revision rates are still found and almost
no subgroup of device-patient-head size combinations was predicted to satisfy the NICE
benchmark for revision. This registry evidence points to a high probability of RS failure relative
to THR, and suggests that resurfacing should be abandoned for women until good comparative
evidence is available that shows that in young active women RS is at least as successful as THR.
For male recipients of RS devices it was possible to identify patient-head size-devicemanu-
facturer subgroups predicted to satisfy benchmark performance retrospectively. However, for
five of the six manufacturers of the most commonly used devices, such subgroups represented
less than half of device recipients. Only the BirminghamHip, Biomet and Finsbury devices
delivered appreciable proportions of patients predicted to performwithin benchmark (85%,
43% and 25% respectively).When the cost-effectiveness of resurfacing relative to alternative
THR prostheses was compared using these manufacturer device-patient subgroups, there
appeared little likelihood that resurfacing in these groups has represented a cost-effective
deployment of health provider resources. Furthermore, it is clear that without retrospective
selection of better performing RS subgroups, the proposition that resurfacing should be contin-
ued for male patients on the grounds of cost-effectiveness cannot be supported.
Strengths, limitations and previous analyses
The most significant limitation is the discrepancy in age distribution between resurfacing and
THR recipients. This means that comparing the two types of intervention requires modelling
THR revision rates outside of the observed age distribution, by controlling for age as a covari-
ate. Unfortunately, there is no viable alternative to this approach because of the lack of compar-
ative studies. A further difficulty is the inability to control for physical activity of patients or
surgeon experience,which are likely to impact on the probability of device failure. Our
approach to some of these difficulties has followed that of others in using flexible parametric
models [5,12,13]. McMinn (2015) [31] has suggested that to gain experience in RS a surgeon
would need to conduct about 1,000 operations; a large number in the context of the total inter-
ventions for some RS devices recorded in the NJR.Whether a similarly prolonged learning
curvemay be required for THR is unknown.McMinn has suggested poor performance of
Cost-Effectiveness of Metal-On-Metal Resurfacing Procedures versus Total Hip Replacement
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small cup size RS devices in female recipients may be attributable to their use by relatively inex-
perienced surgeons [31].
Several weaknesses in our cost-effectiveness analyses must be acknowledged, stemming
from uncertainties about model input parameters. In particular, there is no information about
long term quality of life following implantation of the different types of hip replacement of
interest, or about long term device survival following the different implants examined here.
The AlbertaHip Improvement Project study compared 3, 12 and 24 month SF-36 physical
function changes from baseline for propensity matched BirminghamHip and THR patients. In
this study there was considerable missing data and a 3 month advantage for RS almost disap-
peared by 2 years [32]. A further limitation is that NHS Supply Chain costs are unlikely to per-
fectly reflect real world costs because of variable and individual contractual arrangements
betweenNHS Trusts and prosthesis manufacturers, and potential economies of scale. Our
analyses do not include costs for monitoring plasma cobalt levels; now recommended for
patients followingMOM implants, and this might slightly bias results in favor of RS [33–34].
Nevertheless, our analyses use IPD which reflect real world use of hip replacements in England
andWales over the recent decade, and provide estimates of lifetime cost-effectiveness that will
be of interest to decisionmakers. Estimating life time revision rates requires modelling sub-
stantially beyond the observeddata and the results are sensitive to the model chosen.
This is the first lifetime cost-effectiveness analysis using data from the National Joint Regis-
try England andWales on RS devices satisfying the ten year NICE benchmark. An early analy-
sis by Vale et al (2002) compared RS with THR as a generalized intervention but was limited
by the immaturity of available revision data [25]. Edlin et al. undertook cost-effectiveness anal-
ysis over a one year time horizon using cost and clinical data simultaneously collected from a
randomized controlled trial [26]. This analysis did not capture important differences between
devices in terms of long term revision requirements. Heintzbergen et al. (2013) undertook a 15
year analysis and compared the best performing RS device (BirminghamHip) with the general-
ity of THR devices,most of which were used for older patients [35]. This analysis tends to bias
in favor of RS, and since RS is now mainly justified on the grounds of its potential long term
benefit in delaying requirement for revision a longer time horizon appears more appropriate.
Like other cost-effectiveness analyses of hip replacement we assumed equal mortality for
recipients of different devices [17, 36, 37,38]. Two recent UK observational studies proposed
better survival after RS than THR, but the authors acknowledged their conclusions were prob-
lematic due to the influence of hidden confounders [10, 39].
Conclusion
In conclusion, the cost-effectiveness case for the use of RS as a general class of intervention for
young patients with osteoarthritis is weak.We would suggest that much of the past use of RS
has probably been wasteful of NHS resources. Alternative THR devices are likely to be equally
or more cost-effective. In the absence of good comparative evidence, RS is difficult to justify on
the grounds of either cost-effectiveness or on the basis of preferable revision rates.
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